medical decision support medical decision support
Sign In

Risk Factors of Said et al for Bullous Pemphigoid Following Immune Checkpoint Inhibitor Therapy

Description

Said et al reported risk factors for bullous pemphigoid developing in a patient with cancer being treated with a checkpoint inhibitor. The authors are from Brigham and Women's Hospital, Harvard Medical School, Dana-Farber Cancer Institute, Massachusetts General Hospital and Yale University.


Patient selection: immune checkpoint inhibitor (ICI) therapy

 

Outcome: bullous pemphigoid

 

Risk factors for development of bullous pemphigoid:

(1) age >= 70 years (OR 2.3)

(2) melanoma (OR 3.2)

(3) non-melanoma skin cancer (OR 8.3)

(4) complete or partial response on initial restaging imaging (OR 3.4)

 

Development of bullous pemphigoid is associated with improved tumor response.


To read more or access our algorithms and calculators, please log in or register.

Specialty